Article Text

Download PDFPDF
EP794 A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy
  1. HC Bartels1,
  2. AC Rogers2,
  3. D O’Brien3,
  4. R McVey3,
  5. WD Boyd3 and
  6. DJ Brennan4,5
  1. 1Ireland East Hospital Group Gynaeoncology Group, Mater Misericordiae University
  2. 2Department of Surgery, Mater Misericordiae Dublin
  3. 3Ireland East Hospital Group Gynaeoncology Group, St Vincents University Hospital
  4. 4Ireland East Hospital Group Gynaeoncology Group, Mater Misericordiae Dublin
  5. 5University College Dublin, Dublin, Ireland


Introduction/Background The aim of this metanalysis is to compare the morbidity and mortality in patients undergoing Primary Cytoreductive Surgery (PCS) compared to Neoadjuvant Chemotherapy (NACT) and Interval Cytoreductive Surgery (IDS) for advanced ovarian cancer.

Methodology A literature search using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed for publications reporting morbidity and mortality in patients undergoing PCS compared to NACT and ICS. A total of 1341 citations were reviewed; 17 studies comprising 3759 patients were selected for the analysis.

Results Patients in the PCS group were significantly more likely to have a Clavien-Dindo grade ≥3 morbidity with an overall rate of 21.2% compared to 8.8% (95% CI 1.9–4.0, p<0.0001). Patients in the PCS group were more likely to die within 30 days of surgery (OR 6.1, 95% CI 2.1–17.6, p=0.0008). Patients who underwent NACT + ICS had significantly shorter procedural times (MD −35 minutes, p=0.01), lost less blood intraoperatively (MD −382 ml, p<0.001) and had an average admission 5.0 days shorter (MD −5.0 days, 95% CI −8.1 – −1.9 days, p=0.002) than those undergoing PCS. Patients undergoing NACT were twice as likely to receive optimal and complete cytoreduction (OR 1.9, 95% CI 1.3–2.9, p=0.001, and OR 2.2, 95% CI 1.5–3.3, p=0.0001 respectively).

Conclusion While NACT and IDCS resulted in significantly less morbidity and mortality with improved complete cytoreduction rates compared to PCS, this did not confer improved survival. Hence NACT is a feasible alternative in particular for patients with co-morbidities or high tumour burden.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.